CDA | Evidence Driven
CDA | Evidence Driven

Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Export to CSV
Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Ozurdex dexamethasone intravitreal implant Diabetic macular edema Do not reimburse Complete
Ozurdex Dexamethasone intravitreal implant Macular edema, central retinal vein occlusion Do not list Complete
Ozurdex dexamethasone intravitreal implant Non-infectious uveitis Canada’s Drug Agency is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Padcev enfortumab vedotin Locally advanced or metastatic urothelial carcinoma Reimburse with clinical criteria and/or conditions Complete
Padcev enfortumab vedotin Metastatic urothelial cancer Active
Palynziq pegvaliase Phenylketonuria Reimburse with clinical criteria and/or conditions Complete
Pantoloc M Pantoprazole magnesium Gastric acid secretion, reduction of List in a similar manner to other drugs in class Complete
Paxlovid nirmatrelvir/ritonavir Mild-to-moderate COVID-19, treatment Reimburse with clinical criteria and/or conditions Complete
pdp-levETIRAcetam Levetiracetam Epilepsy Reimburse with clinical criteria and/or conditions Complete
Pegasys RBV Peginterferon alfa-2a and Ribavirin Hepatitis C, chronic List in a similar manner to other drugs in class Complete
Last Updated : July 28, 2024